ANN ARBOR, Mich. — DNA from Helicobacter pylori, a common stomach bacteria, minimizes the effects of colitis in mice, according to a new study by University of Michigan Medical School scientists.
The study published in Gut this month was performed by a team of investigators assembled by senior author John Y. Kao, M.D. of the University of Michigan’s Division of Gastroenterology and assistant professor in U-M’s Department of Internal Medicine. The findings indicate that DNA from H. pylori significantly ameliorates the severity of colitis, say lead authors Jay Luther, M.D. and Stephanie Owyang, an undergraduate student on the team.
Colitis involves inflammation and swelling of the large intestine that leads to diarrhea and abdominal pain. Approximately 3.3 million people in the U.S. suffer from colitis.
More than half of the people in the world are infected with H. pylori, although only about 20 percent of U.S. residents have it. In the U.S., H. pylori infection is treated in patients with stomach ulcers or cancers with antibiotics, but the majority of infected individuals don’t notice they have it and may not develop ulcers or cancers. “This research shows further evidence that we should leave the bugs alone because there may be a benefit to hosting them in the stomach”, says Kao.
“H pylori has co-existed with the human race for more than 50,000 years and although it is linked with peptic ulcer disease and stomach cancer, only a minority of infected patients will develop those complications,” says Luther, adding that less than 15 percent of H. pylori-infected patients develop peptic ulcer disease and less than 1 percent develop cancer.
The researchers aren’t advocating infecting people with H. pylori to treat colitis, but say this may indicated that those already carrying the bacteria should not be treated unless they develop symptoms. These findings also raise significant concerns about global vaccination against H. pylori.
“This bug could be good for you, and we need to understand better what it does,” says Owyang.
The H. pylori infection is more commonly found in developing countries or those with poor sanitation, where colitis, Salmonella and inflammatory bowel diseases are less common. Most people contract H. pylori in their first seven years of life, most commonly through an oral-fecal route.
In the study, researchers found that H. pylori DNA is uniquely immunosuppressive containing high numbers of sequences known to inhibit inflammation. They isolated the DNA from both H. pylori and another bacterium, E. coli, for further comparison. They found that mice receiving H. pylori DNA displayed less weight loss, less bleeding and greater stool consistency compared with mice infected with E coli DNA.
“With one dose, there was a significant difference in the bleeding and inflammation in the colon,” says Luther. “However, further study is needed to define other potential protective measures that H. pylori may provide and its safety as a treatment in patients.”
In previous research, U-M gastroenterologists also found that H. pylori reduced the severity of inflammation of the colon caused by Salmonella in mice.
“It is amazing that the bacterial DNA not only directs the biological behavior of the bacteria, but also has a significant influence on gut immunity of the host. This information might have important implications down the line in our understanding of disease manifestation,” says Owyang.
Additional authors: Of the U-M Medical School: Tomomi Takeuchi, Tyler S. Cole, Min Zhang, Maochang Liu, M.D., John Erb-Downward, M.D., Joel Rubenstein, M.D., MSc (also of the Veterans Affairs Ann Arbor Healthcare System) Anna V. Pierzchala and Jose A. Paul. Of Taipei Veterans General Hospital: Chun-Chia Chen.
Journal reference: doi:10.1136/gut.2010.220087
Funding: National Institutes of Health and AGA-Broad Foundation Student Research Fellowship Award.
About the University of Michigan’s Division of Gastroenterology: U-M has one of the largest gastroenterology practices in the country and is a leader in the prevention, diagnosis, and treatment of diseases of the gastrointestinal tract and liver. Our 50-plus physicians are experts in the diagnosis and treatment of all diseases of the gastrointestinal system, from simple to complex, including those of the esophagus, stomach, small intestine, colon, rectum, liver, gallbladder, pancreas and biliary tract.
In addition to being leaders in the clinic, our faculty are also leaders in their respective areas of research, which span such varied interests as the role of peptides in the brain-gut interactions in functional bowel diseases to innovative treatments of viral hepatitis and liver cancer.
- Mary Masson: email@example.com 734-764-2220